This year alone, 215,000 women will be diagnosed with breast cancer. And sadly, not all of them will be treated equally.

Researchers reported last Tuesday that breast cancer patients who are either obese or poor are more likely to receive lower doses of chemotherapy. This might be why some women relapse and others do not, according to the researchers whose findings appear in the Journal of Clinical Oncology.

This treatment discrepancy seems to stem from doctors who mean well and want to save certain women from severe side effects of chemotherapy. Doctors may be under-dosing obese patients, for example, because a larger dose based on weight could lead to worse side effects. There is no evidence this is true, however.

As for socioeconomic status, researchers report doctors are assuming less-educated patients won't stick with a tough course of treatment -- and so they prescribe less, in hopes patients will complete the regimen.

Researchers found that severely obese women were four times more likely to get less chemotherapy than they need. Women with less than a high school education were three times more likely to receive low doses of chemotherapy. And women living in the South were almost six times more likely to come up short on the drugs they need to save their lives.

"We have new therapies and cures out there for many forms of cancer and sadly, sometimes we're not curing people because they are not getting the full doses that should be standard," says Dr. Gary Lyman who led the study at the University of Rochester Medical Center in New York.

Scientists from Harvard University and Massachusetts Institute of Technology (MIT) are developing a tiny implant that will allow doctors to see what's happening with tumors from the inside out.

If all proceeds according to plan, doctors will one day be implanting tiny sensors inside tumors to determine whether or not cancer drugs are shrinking the tumors. The sensors will also determine whether or not tumors are growing.

Cancer specialists have long wished for better methods of measuring the success of drugs. While blood tests can show if a drug has reached the bloodstream, they don't reveal much about the tumor itself. This small silicone cube, no bigger than two millimeters on each side and embedded in a tumor or lymph node, would remain in the body throughout treatment while essentially broadcasting what's going on inside the tumor.

MIT scientists hope to begin animal experiments within months. Their goal is to one day make the implant as thin as the pieces of led used in mechanical pencils.

This research, funded by the National Cancer Institute, is part of a long-term project to make medical technologies that will cure cancer. It's all part of journey toward complete targeted cancer treatment. And this little implant will have the power to communicate whether or not these treatments are working.

Oncotype DX is a diagnostic test that quantifies the likelihood of disease recurrence in women with early stage, node negative breast cancer. With the information provided by the test it may be possible for doctors and patients to make more informed decisions about breast cancer treatment options.

Oncotype DX analyzes a specific set of genes within a tumor to determine a recurrence score. The recurrence score is a number between 0 and 100 that corresponds to the likelihood that a recurrence with happen within 10 years of initial diagnosis.

Results presented at the 2006 annual San Antonio Breast Cancer Symposium (SABCS) stated that the Oncotype DX test can more accurately predict estrogen receptor (ER) status than the two other commonly used tests, immunohistochemistry and ligand binding.

Another Oncotype DX study presented at the SABCS said that the test could predict the response to Tamoxifen by the levels of estrogen expression.

The researchers concluded that ER and PR expression, as measured using the Oncotype DX test, provide different pieces of information about prognosis and likely response to Tamoxifen among patients with node-negative breast cancer.

Cervical cancer was once the most common cancer in women. But between 1955 and 1992, the number of cervical cancer deaths dropped by 74 percent -- thanks to increased use of the Pap test, a screening tool that can find changes in the cervix before cancer develops and can also detect cancer in its most curable stage. The Pap test is still widely used. And the cervical cancer death rate continues to drop four percent every year.

In 2006, about 9,700 new cases of invasive cervical cancer will be diagnosed in the United States. About 3,700 women will die from the disease. Non-invasive cervical cancer is believed to be four times more common than the invasive form of the disease. Nearly all of these cases can be cured.

Cervical cancer typically occurs in women between the ages of 35 and 55 and rarely in women under the age of 20. It affects mostly Hispanic women, and African-American women develop the disease 50 percent more often than non-Hispanic white women. Women most as risk for cervical cancer are smokers, those with HIV or chlamydia infections, those with diets low in fruit and vegetable consumption, those who between 1940 and 1971 took the hormonal drug DES, and those who have taken oral contraceptives for extended periods of time. Women who have had multiple pregnancies, have a family history of the disease, and have a low socio-economic status are also at risk. Those most at risk, however, are women with human papilloma virus.

Human papilloma virus (HPV) is the most common risk factor for cervical cancer, and some experts believe a woman must have HPV to contract cervical cancer. There are 100 different types of HPV, 13 of which are likely to cause cervical cancer through sexual contact. There are usually no symptoms of HPV, but possible signs of cervical cancer can include vaginal bleeding, unusual discharge, pelvic pain, and pain during sexual intercourse.

There are two ways to stop cervical cancer. First, women can protect themselves against HPV. Protection comes in the form of delaying sexual activity, limiting the amount of sexual partners and their partners, using condoms (thought to be 70 percent effective) and receiving the cervical cancer vaccine, recommended for use in females ages 11-26. The vaccine is most effective for women who have never been sexually active. Second, women can receive regular Pap tests in order to catch pre-cancers. Pap tests are recommended for women three years after their first sexual encounter and before the age of 21 -- and then every year after that.

An abnormal Pap test typically prompts a colposcopy -- a technique that uses a scope to examine the cervix. Diagnosis usually stems from a combination of other scoping methods, pelvic exams, imaging tests, and biopsies used to confirm the presence of cancer and to stage the disease. Stages range from 0-4.

For non-invasive cervical cancer, surgery -- ranging from removal of the cancerous tissue to hysterectomy -- may be the only treatment necessary. For invasive forms of the cancer, surgery is often followed by radiation and chemotherapy. Women interested in preserving their fertility should discuss options with their physicians.

The state of cervical cancer has come a long way over the years. And this year, two critical developments emerged. In June 2006, the FDA approved the first drug for late-stage cervical cancer. The drug, Hycamtin, is recommended for use in combination with chemotherapy. Also is June, the cervical cancer vaccine, Gardasil, was released. Both developments are monumental -- and both will undoubtedly help decrease the already-dropping cervical cancer death rate.

For more information about cervical cancer, visit the following sites:

American Cancer Society
Mayo Clinic
Medline Plus
National Women's Health Information Center

I love the terminology used by those behind the scenes at Hurricane Voices. This is where I first read the words breast cancer dancer and where individuals have gathered to advance the rebellion against breast cancer. The content on this site is powerful, edgy, and truly inspiring -- it incites public action. And it makes me want to jump up and do something -- now. To break down the barriers to progress in pursuit of the causes and cures for breast cancer -- which is the whole purpose of Hurricane Voices.

Hurricane Voices began because of one woman -- Lois Egasti, a wife and mother living with metastatic breast cancer. Lois, who passed away on April 15, 2003, knew she was not alone and felt the need to take a stand against the disease. So she put her urge into action and formed this not-for-profit organization. And in just four years, a great community of voices emerged -- voices that have helped raise support and participation in far-reaching programs and events.

Hurricane Voices offers on its website a family reading list, a regular newsletter, an empowering overview of breast cancer and its statistics, and a sampling of various myths surrounding breast cancer. Hurricane Voices provides direction for involvement in unique conferences -- such as When a Parent Has Cancer: Strengthening the School's Response which helps school systems support families affected by parental cancer and Breast Cancer: Truth & Consequences, a conference that challenges the status quo concerning breast cancer. Hurricane Voices initiates thought-provoking public awareness campaigns and strives to inform the public that the disease we call breast cancer is a very serious illness.

Every day, more people are being diagnosed. Every day, more people are dying. Yet we are not beating this disease -- in fact in the time it takes to brush our teeth or drink a cup of coffee, another person has died of breast cancer. And this is what Hurricane Voices wants us to know. This and the fact that well-meaning, misconstrued survival rates in the 90 percentiles only extend for five years. And five years is just not enough.

Powerful -- that's what Hurricane Voices is -- powerful. And each of us can contribute our own power to this organization by becoming a Hurricane Voice. So speak up -- by simply clicking here.

In previous Boobs bouncing blogs bouncing boobs for a cause, Bouncing for boobs boobs bouncing countdown, Boobeque bouncing for boobs barbeque and Bouncing for Boobs: 100 days 1 million boobs bounced $10,000! posts, we have been following the progress of Priscilla as she blogged the Bouncing for Boobs campaign with the goal to bounce one million times in 100 days to raise $10,000 dollars to help her single mom sister Kathleen keep the lights on and food in the pantry when chemotherapy drained her of any energy to get up and go to work. It was a single effort by a single person to make a difference in a sister's life.

On June 4, Bouncing for Boobs did indeed reach the one million times in 100 days mark and raised $10,000 dollars.

In the process of helping her sister Kathleen, the campaign grew larger than the single effort Priscilla originally intended, and last week, Priscilla blogged at Bouncing for Boobs that the non-profit organization she launched to help single mothers worldwide who face financial concerns of providing for their children while undergoing chemotherapy and cannot work, has taken steps to receive official charity status. Bouncing for Breast Cancer is on its way, and if the past is an indicator of the future, with Priscilla at the helm, success for the Bouncing for Breast Cancer organization is inevitable.